8-K: Elevation Oncology Halts EO-3021 Development, Focuses on EO-1022 and Strategic Options

Elevation Oncology discontinues development of EO-3021, a Claudin 18.2 ADC, while advancing EO-1022, a HER3 ADC, and exploring strategic alternatives to maximize shareholder value.

Summary

• Elevation Oncology announced the discontinuation of EO-3021 development on March 20, 2025, due to insufficient efficacy data from its Phase 1 trial.
• The Phase 1 trial of EO-3021 showed an objective response rate of 22.2% and a disease control rate of 72.2% among 36 evaluable patients with gastric or gastroesophageal cancer.
• The company will now focus on advancing EO-1022, a HER3 ADC, and is initiating a process to evaluate strategic options.
• Elevation Oncology is implementing a workforce reduction of approximately 70% as part of a corporate restructuring.
• The company estimates $3 million in costs related to the workforce reduction, with most payments expected by the end of June 2025.
• Elevation Oncology expects its cash, cash equivalents, and marketable securities of $93.2 million as of December 31, 2024, to fund operations into the second half of 2026.
• Chief Medical Officer Valerie M. Jansen will step down effective March 31, 2025, and will continue to assist the company as a consultant.
• Preclinical data for EO-1022 is planned to be presented at the AACR Annual Meeting 2025 and an Investigational New Drug (IND) application is expected in 2026.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The discontinuation of EO-3021 and workforce reduction are negative, but the focus on EO-1022 and extended cash runway are positive. The exploration of strategic options introduces uncertainty.

Positives

• Elevation Oncology is focusing on EO-1022, a HER3 ADC, which incorporates glycan site-specific conjugation and is designed to address significant and emerging unmet needs in many HER3-expressing cancers.
• The company has a cash runway into the second half of 2026.
• Elevation Oncology is evaluating strategic options to maximize shareholder value.

Negatives

• Elevation Oncology is discontinuing development of EO-3021 due to insufficient efficacy data.
• The company is implementing a workforce reduction of approximately 70%.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that may cause actual activities or results to differ significantly.
• These risks include the ability to advance product candidates, the timing and results of preclinical studies and clinical trials, and the ability to fund development activities.

Future Outlook

Elevation Oncology will focus on advancing EO-1022, a HER3 ADC, and is evaluating strategic options to maximize shareholder value. The company expects its current cash position to fund operations into the second half of 2026.

Management Comments

• 'Despite continuing to demonstrate differentiated safety as a more combinable ADC, updated efficacy data suggest that treatment with EO-3021 does not meet our bar for success and is insufficient to provide patients a competitive benefit-risk profile compared to other Claudin 18.2 ADCs in development,' said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
• Mr. Ferra stated that the company is turning its focus to its potentially differentiated HER3 ADC, EO-1022.
• Mr. Ferra expressed gratitude to the employees who will be departing as part of the restructuring.

Industry Context

The decision to discontinue EO-3021 development reflects the competitive landscape of Claudin 18.2 ADCs and the need for therapies with a strong benefit-risk profile. The focus on HER3 ADCs aligns with the growing interest in targeting HER3-expressing cancers.

Comparison to Industry Standards

• The 22.2% ORR observed with EO-3021 in a biomarker-enriched population is lower than some other Claudin 18.2 ADCs in development, leading to the decision to discontinue its development.
• Companies like Astellas and Ganymed have also been developing Claudin 18.2-targeted therapies, setting a high bar for efficacy and safety.
• The focus on HER3 ADCs puts Elevation Oncology in competition with companies like Daiichi Sankyo and AstraZeneca, which are also developing HER3-targeted therapies.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the discontinuation of EO-3021 and the evaluation of strategic options.
• Employees are impacted by the workforce reduction of approximately 70%.
• Patients may be impacted by the change in focus to EO-1022 and the potential for new therapies targeting HER3-expressing cancers.

Next Steps

• Advance EO-1022 through preclinical development.
• Present preclinical data for EO-1022 at the AACR Annual Meeting 2025.
• File an Investigational New Drug (IND) application for EO-1022 in 2026.
• Evaluate strategic options to maximize shareholder value.

Key Dates

Keywords

Elevation Oncology, EO-3021, EO-1022, Antibody-drug conjugate, ADC, HER3, Claudin 18.2, Clinical trial, Workforce reduction, Strategic options, Cash runway, Oncology